Panagora Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Panagora Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,341	Closed	-$104K	–	2314
2021 Q2	$104K	Sell	1,341 -3,265	-71%	-$248K	﹤0.01%	1891
2021 Q1	$343K	Buy	4,606 +1,817	+65%	+$168K	﹤0.01%	1501
2020 Q4	$475K	Sell	2,789 -2,369	-46%	-$351K	﹤0.01%	1246
2020 Q3	$724K	Buy	5,158 +272	+6%	+$41.3K	﹤0.01%	1018
2020 Q2	$783K	Buy	4,886 +4,060	+492%	+$552K	0.01%	1019
2020 Q1	$81K	Buy	+826	New	+$94.4K	﹤0.01%	1753
2019 Q3	–	Sell	-70	Closed	-$11K	–	2623
2019 Q2	$11K	Hold	70	–	–	﹤0.01%	2389
2019 Q1	$8K	Hold	70	–	–	﹤0.01%	2380
2018 Q4	$8K	Hold	70	–	–	﹤0.01%	2340
2018 Q3	$11K	Buy	+70	New	+$9.57K	﹤0.01%	2298
2016 Q1	–	Sell	-614	Closed	-$24K	–	2340
2015 Q4	$24K	Sell	614 -4,043	-87%	-$131K	﹤0.01%	2122
2015 Q3	$150K	Sell	4,657 -10,936	-70%	-$371K	﹤0.01%	1690
2015 Q2	$474K	Buy	+15,593	New	+$319K	﹤0.01%	1349

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Panagora Asset Management's SRPT Position: Q3 2021 in Review

Panagora Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 1,341 shares — an estimated $104K sold.

Panagora Asset Management first reported a position in SRPT in Q2 2015 and held it in 13 quarters. The position peaked at $783K in Q2 2020. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

Panagora Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
Panagora Asset Management sold 1,341 Sarepta Therapeutics shares in Q3 2021, an estimated $104K.
Panagora Asset Management first reported a position in Sarepta Therapeutics in Q2 2015 and held it in 13 quarters.
Panagora Asset Management's Sarepta Therapeutics position peaked at $783K in Q2 2020.
306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.